New Mexico Statutes Chapter 26. Drugs and Cosmetics § 26-2D-3. Definitions

A. “board” means the medical psilocybin advisory board;

B. “clinician” means an approved health care provider licensed in New Mexico who holds a permit from the department to provide medical services to qualified patients;

C. “department” means the department of health;

D. “medical services” means services provided to a patient in an approved setting before, during and after the ingestion of psilocybin and includes a preparation session, an administration session and an integration session;

E. “producer” means a person who has a permit from the department to grow and harvest or prepare psilocybin from psilocybin-producing mushrooms, including to compound, convert, process or manufacture psilocybin products directly or indirectly from psilocybin mushrooms and to package or repackage or label or relabel the products;

F. “program” means the medical use of psilocybin program;

G. “psilocybin” means the naturally occurring psychedelic compound 4-phosphoryloxy-N,N-dimethyltryptamine, also known as 4-PO-DMT, and its pharmacologically active metabolite psilocin, 4-hydroxy-N,N-dimethyltryptamine, found in certain mushrooms, but does not include synthetic or synthetic analogs of psilocybin;

H. “qualified patient” means a patient whose clinician has judged the patient to be a medically appropriate candidate for the use of medical psilocybin based on being diagnosed with a qualifying condition;

I. “qualifying condition” includes:

J. “secretary” means the secretary of health.